CN107970367A - A kind of Maca composite for improving glucose -lipid metabolism disorder - Google Patents
A kind of Maca composite for improving glucose -lipid metabolism disorder Download PDFInfo
- Publication number
- CN107970367A CN107970367A CN201711329213.9A CN201711329213A CN107970367A CN 107970367 A CN107970367 A CN 107970367A CN 201711329213 A CN201711329213 A CN 201711329213A CN 107970367 A CN107970367 A CN 107970367A
- Authority
- CN
- China
- Prior art keywords
- maca
- water extract
- water
- sealwort
- campanulaceae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000000759 Lepidium meyenii Species 0.000 title claims abstract description 78
- 235000000421 Lepidium meyenii Nutrition 0.000 title claims abstract description 78
- 235000012902 lepidium meyenii Nutrition 0.000 title claims abstract description 78
- 239000002131 composite material Substances 0.000 title claims abstract description 48
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 24
- 239000008103 glucose Substances 0.000 title claims abstract description 24
- 208000017170 Lipid metabolism disease Diseases 0.000 title claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 110
- 241000208671 Campanulaceae Species 0.000 claims abstract description 31
- 230000036541 health Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 26
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 21
- 239000012074 organic phase Substances 0.000 claims description 14
- 239000012071 phase Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000012545 processing Methods 0.000 claims description 12
- 238000005119 centrifugation Methods 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000003809 water extraction Methods 0.000 claims description 6
- 238000007792 addition Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 238000002137 ultrasound extraction Methods 0.000 claims description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 206010018473 Glycosuria Diseases 0.000 claims description 3
- 241000675108 Citrus tangerina Species 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- -1 fully After mixing Substances 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 abstract description 17
- 229920002527 Glycogen Polymers 0.000 abstract description 7
- 229940096919 glycogen Drugs 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 35
- 230000000052 comparative effect Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 229930186217 Glycolipid Natural products 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Maca composite, and by weight, the Maca composite includes following component：0.25~2 part of maca water extract, 0.25~2.5 part of sealwort water extract, 0.25~2.5 part of campanulaceae water extract；The Maca composite can be applied to improve on glucose -lipid metabolism disorder medicine or health products.Each component component acts synergistically jointly in Maca composite of the present invention, promotes cell sugar to absorb, promotes the synthesis of intracellular glycogen, while reduces intracellular TC contents, reduces intracellular ROS level, obtains improving the Maca composite of glucose -lipid metabolism disorder.
Description
Technical field
The present invention relates to nutrition and health care field, and in particular to a kind of Maca composite for improving glucose -lipid metabolism disorder.
Background technology
With economical fast development and the change of people's eating patterns, excessively the becoming more meticulous of grain processing, excess fat
An important factor for having become influence health of masses with the intake of albumen.While rapid economic development, various metabolics move back
The incidence of the chronic disease such as row disease and cardiovascular and cerebrovascular is increasingly soaring, it has also become the great public health problem in the whole world.Its
In, onset diabetes crowd is numerous, and complication is serious, it has also become one of slow disease of particular concern to people.According to international diabetes
Alliance reports that global diabetic's number is up to 3.82 hundred million, and all types diabetes prevalence is rising, and China's glycosuria
Patient's (adult) just there are about 1.14 hundred million, account for the 30% of global diabetes population.In addition, China pre-diabetic there are about
4.93 hundred million, it is potential diabetic, compared with remote districts, the illness rate of urban population and developed area is more
It is high.It is reported that the social cost of diabetic population is up to more than 4,000 hundred million yuan, huge burden on society, which will become the Chinese government, needs face
The great social problem faced.
Research finds that slow disease occurs notable with more greases in diet and carbohydrate (such as sucrose, high fructose syrup) intake
Correlation, this dietary structure changed dramatically in the metabolism status of liver.A large amount of reports show that these energy matters improve blood glucose water
It is flat, and synthesized in body, accumulate for fat, further trigger a series of metabolic problems.For example, free fatty in blood
Horizontal and blood sugar level improves, can induce muscle, liver, adipocyte occur insulin resistance (Insulin resistance,
IR), oxidative stress etc., further results in cellular fat synthesis and metabolic disorder, endocrine disturbance, forms vicious circle, finally
Body glycolipid metabolism is set to get muddled.Liver is a most important organ in body metabolism, and being responsible in terms of lipid metaboli will be sweet
Oil ＆ fat acid is reunited into triglycerides (Triglycerides, TG) in liver cell, then is transported in the form of lipoprotein
Liver, is transported to subcutaneous depot；In terms of glycometabolism, the fructose of metabolism 50%~70%, 20%~30% grape can be responsible for
Sugar.Therefore, once there is glucose -lipid metabolism disorder in liver, easily makes to cause whole body glycolipid metabolism further to change, and triggers glycosuria
Sick chronic diseases.In view of global chronic disease is occurred frequently, the glucose -lipid metabolism disorder Forming Mechanism of liver has received widespread attention, and how to lead to
Cross natural component regulation and control liver glycolipid metabolism and also become research hotspot.
Using glucose -lipid metabolism disorder cell model, efficacy assessments quickly can be carried out from multiple indexs, and can more go deep into
Inquire into its mechanism of action in ground.Therefore, combination of sugar hyperlipoidemia can further study Maca composite to glucose -lipid metabolism disorder
Intervention effect, to blood glucose in order to control or control blood fat food exploitation provide reference, Given this propose the present invention.
The content of the invention
It is an object of the invention to provide a kind of safe and without side-effects, and there is the maca for improving glucose -lipid metabolism disorder to answer
Side, more more options are provided for the patients with chronic diseases diet such as diabetes.
A kind of Maca composite, by weight, including following component：0.25~2 part of maca water extract, sealwort water carry
0.25~2.5 part of thing, 0.25~2.5 part of campanulaceae water extract.
Preferably, the Maca composite includes following component：0.25~1 part of maca water extract, sealwort water extract 0.25~1
Part, 0.25~1 part of campanulaceae water extract；
It is further preferred that the ratio of the sealwort water extract and campanulaceae water extract is 1:1.
Wherein, the maca water extract, and/or sealwort water extract, and/or the use side of preparation as follows of campanulaceae water extract
Method：It is in mass ratio 1 after maca or sealwort or campanulaceae are crushed:15~25 ratio is added to the water, ultrasonic extraction 1~3 time,
Take clear liquid；After carrying out deproteinized processing again, obtained water extract solution, dry powder processed, to obtain the final product.
Wherein, the ultrasonic extraction is specially：At a temperature of being placed on 55 DEG C~65 DEG C, with the power of 220~280W
25~35min of ultrasound, centrifugation, takes clear liquid.
Centrifugation in the ultrasonic extraction specifically uses the rotating speed of 3500~4500rmp, centrifuges 13~17min.
Wherein, the albumen processing includes the following steps：
1) concentrate by clear liquid concentration for 1/3~1/4 volume；
2) it is 3~4 by volume:1 ratio, in the concentrate that step 1) obtains, adds organic solvent, is sufficiently mixed
Afterwards, organic phase and water phase are obtained；
3) water for being obtained step 2) mutually repeats the organic solvent of 2~3 additions, 3~4 times of volumes, after being sufficiently mixed,
Obtain organic phase and water phase；
4) combining step 2) and the organic phase that is obtained of step 3), supernatant is taken after centrifugation, then obtained with step 3)
Water mutually merges, up to water extraction solution.
Wherein, the centrifugation in the albumen processing specifically uses the rotating speed of 2500~3500rmp, centrifuges 8~12min.
Wherein, the organic solvent is chloroform and the mixture of n-butanol；Preferably volume ratio is 3:1 chloroform and positive fourth
The mixture of alcohol.
The preparation method of water extract preferably uses following scheme, the maca water extract, and/or sealwort water extract, and/or
The preparation method of campanulaceae water extract includes the following steps：
1) after crushing maca or sealwort or campanulaceae, 50~70 mesh sieves is crossed, are in mass ratio 1:18~22 ratio adds
In water, at a temperature of being placed on 58 DEG C~62 DEG C, with 28~32min of power ultrasonic of 240~260W, centrifugation, takes clear liquid；Will
The clear liquid concentration is the concentrate of 1/3~1/4 volume；
2) it is 3~4 by volume:1 ratio, in the concentrate that step 1) obtains, adds the mixed of chloroform and n-butanol
Liquid is closed, after being sufficiently mixed, obtains organic phase and water phase；
3) water for being obtained step 2) mutually repeats the chloroform of 2~3 additions, 3~4 times of volumes and the mixed liquor of n-butanol,
After being sufficiently mixed, organic phase and water phase are obtained；
4) combining step 2) and the organic phase that is obtained of step 3), supernatant is taken after centrifugation, what is obtained with step 3)
Water mutually merges, up to water extraction solution, dry powder processed, to obtain the final product；
Wherein, the volume ratio of chloroform and n-butanol is 3:1.
A kind of preferred solution of present invention offer, the Maca composite, by weight, including following component：Maca water
0.8~1.2 part of extract, 0.4~0.6 part of sealwort water extract, 0.4~0.6 part of campanulaceae water extract；The sealwort water extract and described
The mass ratio of campanulaceae water extract is 1:1.
Optimal case provided by the invention, the Maca composite, by weight, including following component：Maca water extract 1
Part, 0.5 part of sealwort water extract, 0.5 part of campanulaceae water extract.
Maca composite of the present invention adds oral formulations or the injection system that pharmaceutically acceptable auxiliary material is prepared
Agent.
The oral formulations include one kind in tablet, capsule, granule, pill or oral liquid.
A further object of the present invention is that any of the above-described Maca composite is improving glucose -lipid metabolism disorder medicine or guarantor
Application on strong product.
Wherein, the medicine or health products are in insulin resistance, diabetes, hyperglycaemia, hyperlipidemia, obesity, fatty liver
Application.
The a kind of of the present invention has the Maca composite for improving glucose -lipid metabolism disorder, and Maca composite is by maca, sealwort and tangerine
The water extract composition of stalk.By the preparation method of extract of the present invention, invalid components can be removed, make active constituent content very big
Improve, make active ingredient definitely.Experiment shows that the Maca composite has the effect for adjusting cytolipin metabolism, Neng Gouxian
Write and promote glucose absorption, promote the synthesis of intracellular glycogen, while reduce intracellular T-CHOL (Total
Cholesterol, TC) content, it is horizontal to reduce intracellular reactive oxygen radical (Reactive Oxygen Species, ROS).
The Maca composite that the present invention filters out can significantly improve liver cell carbohydrate metabolism disturbance symptom, and the Maca composite obtained by the present invention
Safety is without side-effects, can be added to as food ingredient in food.
Embodiment
Following embodiments are used to illustrate the present invention, but are not limited to the scope of the present invention.
The maca water extract used in following examples/sealwort water extract/campanulaceae water extract is according to following preparation method
It is made, the preparation method includes the following steps：
1) after crushing maca or sealwort or campanulaceae, 60 mesh sieves is crossed, are in mass ratio 1:20 ratio is added to the water, by it
At a temperature of being placed in 60 DEG C, with the power ultrasonic 30min of 250W, with the rotating speed of 4000rmp, 15min is centrifuged, takes clear liquid；By institute
State concentrate of the clear liquid concentration for 1/4 volume；
2) it is 3 by volume:1 ratio, in the concentrate that step 1) obtains, adds the mixing of chloroform and n-butanol
Liquid, after being sufficiently mixed, obtains organic phase and water phase；
3) water for being obtained step 2) is mutually repeated 2 times the chloroform of 3 times of volumes of addition and the mixed liquor of n-butanol, fully mixed
After conjunction, organic phase and water phase are obtained；
4) combining step 2) and the organic phase that is obtained of step 3), with the rotating speed of 3000rmp, 10min is centrifuged, takes supernatant
Liquid, then mutually merge with the water that step 3) is obtained, up to water extraction solution, it is freeze-dried powder processed, to obtain the final product；
Wherein, the volume ratio of chloroform and n-butanol is 3:1.
Embodiment 1
The present embodiment provides a kind of Maca composite, is made of following component：1 part of maca water extract, sealwort water extract 0.5
Part, 0.5 part of campanulaceae water extract.
Embodiment 2
The present embodiment provides a kind of Maca composite, is made of following component：0.25 part of maca water extract, sealwort water extract
0.25 part, 0.25 part of campanulaceae water extract.
Embodiment 3
The present embodiment provides a kind of Maca composite, is made of following component：0.5 part of maca water extract, sealwort water extract
0.25 part, 0.25 part of campanulaceae water extract.
Embodiment 4
The present embodiment provides a kind of Maca composite, is made of following component：1 part of maca water extract, sealwort water extract 0.25
Part, 0.75 part of campanulaceae water extract.
Embodiment 5
The present embodiment provides a kind of Maca composite, is made of following component：2 parts of maca water extract, sealwort water extract 0.25
Part, 0.25 part of campanulaceae water extract.
Embodiment 6
The present embodiment provides a kind of Maca composite, is made of following component：1 part of maca water extract, 1 part of sealwort water extract,
1 part of campanulaceae water extract.
Comparative example 1
This comparative example provides a kind of Maca composite, is made of following component：1 part of maca water extract.
Comparative example 2
This comparative example provides a kind of compound, is made of following component：0.5 part of sealwort water extract, 0.5 part of campanulaceae water extract.
Comparative example 3
This comparative example provides a kind of Maca composite, is made of following component：0.25 part of sealwort water extract, campanulaceae water extract
0.25 part.
Comparative example 4
This comparative example provides a kind of Maca composite, is made of following component：1 part of maca water extract, sealwort water extract 0.7
Part, 0.3 part of chrysanthemum water extract.
Comparative example 5
This comparative example provides a kind of Maca composite, is made of following component：1 part of maca water extract, sealwort water extract 0.25
Part, 0.25 part of longan water extract.
Test example 1
By the Maca composite described in embodiment 1~6 and the compound described in comparative example 1~5 in carbohydrate metabolism disturbance cell membrane
Influence experiment in type
1. the preparation of modeling liquid
A certain amount of bovine serum albumin(BSA) (Bovine Serum Albumin, BSA) is weighed, is dissolved in sugar-free without phenol red incomplete
In DMEM culture mediums, with the KOH tune pH to 10 of 10mol/L, ultrasound to clarification.A certain amount of oleic acid and palmitic acid are weighed, is dissolved in
Contain on a small quantity in the corresponding incomplete culture mediums of BSA so that oleic acid and palm fibre in free fatty (Free Fatty Acid, FFA) solution
The molar ratio of palmitic acid acid is 2:1, while the molar ratio of FFA and BSA is 6.6:1, ultrasound to clarification.By BSA-FFA compounds
PH value of solution is adjusted to 7.4, and with 0.22 μm of filter filtration sterilization, it is equal then to add a certain amount of glucose and the fructose mixing weighed
It is even, then go over filter membrane, that is, required modeling liquid is obtained, is saved backup in -20 DEG C.Using preincubation to 37 DEG C.
2. the preparation of sample
The preparation of MTT samples：Maca composite described in embodiment 1~6 and the compound described in comparative example 1~5 is molten
In the DMEM culture mediums of serum-free, the mother liquor of 10mg/mL is configured to, with 0.22 μm of filter filtration sterilization, it is standby to be placed in 4 DEG C of refrigerators
With.
Glycolipid adjusts the preparation of experiment sample：By described in the Maca composite described in embodiment 1~6 and comparative example 1~5
Compound be dissolved in prepared modeling liquid, be configured to the mother liquor of 10mg/mL, with 0.22 μm of filter filtration sterilization, be placed in 4 DEG C
Refrigerator is spare.
3. the in vitro culture of cell is with freezing
HepG 2 cell is incubated at containing 10% newborn bovine serum, penicillin 100U/mL and streptomysin
In the DMEM culture mediums of 100 μ g/mL (DMEM10), in 37 DEG C, containing 5%CO2And 90% relative humidity incubator in it is conventional
Culture.When cell growth to 80%~90% fusion, old nutrient solution is removed, with PBS solution rinse cellular layer, uses trypsase
Vitellophag 5min, after cell disperses, adds 3mL DMEM10 and terminates Trypsin Induced reaction.Cell liquid-transfering gun is beaten
Dissipate and form cell suspension, cell passage can be carried out, place cellar culture in incubator.
When HepG 2 cell need to freeze, old nutrient solution is removed, with PBS solution rinse cellular layer, with pancreas egg
White enzymic digestion cell 5min, after cell disperses, adds 3mL DMEM10 and terminates Trypsin Induced reaction.By cell liquid relief
Rifle is broken up to form cell suspension, collects and centrifuges, abandons culture medium, frozen stock solution (10%DMSO) is added into cell, immigration freezes
Pipe, and mark.Cryopreservation tube equipped with cell is put into 4 DEG C of refrigerators, about 30min is then placed in -20 DEG C of refrigerators, about 30~
60min, is placed in -80 DEG C of ultra low temperature freezers and stands overnight, be placed in liquid nitrogen container and preserve for a long time.
4.MTT methods measure cell survival rate
96 well culture plates are taken, 100 μ L cell suspensions are added per hole, HepG2 cell concentrations are 1 × 105A/mL, 37 DEG C of cultures
Nutrient solution is discarded after 24h, with PBS cleaning once, the 100 μ L for the treatment of fluid of different disposal are added per hole, with the identical of no detectable substance
Culture medium incubated cell is control, and nutrient solution is removed after cultivating 24h, adds 0.5mg/mL MTT-DMEM and is incubated in 37 DEG C of lucifuges
4h, adds 100 μ L DMSO, and concussion is mixed to be completely dissolved out MTT purple crystal products.Measured with microplate reader at 490nm
Absorbance.Remaining group cell survival rate is calculated using the cell survival rate of cellular control unit as 100%.
5. cell conditioned medium glucose assays
After each group cell sample-adding processing 24h, 5 μ L cell supernatants to be measured are taken, supernatant is measured with Glucose estimation kit
Glucose content, as a result divided by model group glucose content percentage represent (%).
6. the measure of intracellular glycogen content
After each group cell sample-adding processing 24h, nutrient solution is carefully discarded, PBS is washed 1 time, and cell is cracked with RIPA lysates, is used
Glycogen kit measurement intracellular glycogen content.As a result divided by the percentage of model group glycogen content represents result to be final.
7. the measure of supernatant and intracellular TG contents
After each group cell sample-adding processing 24h, 50 μ L cell supernatants to be measured are taken, with TG kit measurement TG contents, as a result
Represented (%) with the percentage of model group TG contents.
After each group cell sample-adding processing 24h, nutrient solution is carefully discarded, by cell to be determined in plate with after PBS rinses 2 times,
Add RIPA lysates.Fully after cracking, with TG kit measurement TG contents.As a result represented with the percentage of model group TG contents
(%).
8. intracellular TC assays
After each group cell sample-adding processing 24h, nutrient solution is carefully discarded, PBS is washed 1 time, and cell is cracked with RIPA lysates, is used
TC kit measurement intracellular cholesterol levels.As a result divided by the percentage of model group TC contents represents result to be final.
9.DCFH-DA methods measure intracellular ROS
The action principle of fluorescence probe DCFH-DA：DCFH-DA is a kind of most common fluorescence probe, to OH,
ONOO, ROO, isoreactivity oxygen have very sensitive test limit.DCFH-DA does not have fluorescence in itself, can pass freely through cell membrane, quilt
The lipase hydrolysis of intracellular simultaneously produces DCFH.Intracellular active oxygen further aoxidizes DCFH, DCF of the generation with fluorescence, its
Reactive oxygen species in fluorescence intensity reacting cells.By the cell of processing with the HBSS containing 25 μM of DCFH-DA under the conditions of 37 DEG C
Cultivate 30min.Cleaned twice with HBSS, the rear HBSS for adding 100 μ L.With cell in microplate reader 96 hole blackboards of measure in 490nm
Transmitting light of the fluorescent material DCF under 535nm wavelength under the exciting light of wavelength.As a result with the percentage table of model group ROS levels
Show (%).
10. statistical procedures
Data are handled using Origin Lab statistical softwares, experimental result is represented with mean value ± standard error (Mean ± SD)
As a result with analysis
(1) influence of the Maca composite cell proliferation of embodiment 1~6, Details as Follows table：
Table 1
| Cell survival rate (%) | |
| Control group | 100.00000±3.65206 |
| Embodiment 1 | 100.23718±4.24415 |
| Embodiment 2 | 103.49912±4.45449 |
| Embodiment 3 | 100.76441±6.41922 |
| Embodiment 4 | 71.96824±3.22772 |
| Embodiment 5 | 67.13672±2.07013 |
| Embodiment 6 | 48.93799±7.66209 |
As seen from the above table, the Maca composite cell proliferation unrestraint effect described in embodiment 1~3, the institute of embodiment 4~6
The Maca composite stated suppresses cell Proliferation.
(2) compound of embodiment 1~6 and comparative example 1~5 is to glucose -lipid metabolism disorder cell conditioned medium glucose and intracellular glycogen
The influence of content, Details as Follows table：
Table 2
(3) compound of embodiment 1~6 and comparative example 1~5 is to glucose -lipid metabolism disorder cell intracellular TG's, TC and supernatant TG
Influence, Details as Follows table：
Table 3
(4) influence of the compound of embodiment 1~6 and comparative example 1~5 to glucose -lipid metabolism disorder cell intracellular ROS, details are such as
Following table：
Table 4
It can be seen from the above, the performance of the Maca composite described in embodiment 1~6 is generally higher than comparative example 1~5；Embodiment 1~
In Maca composite described in 6, some differences of effect, when the mass ratio of sealwort water extract and campanulaceae water extract is 1:When 1, compatibility effect
Fruit is more excellent；Wherein, the comprehensive performance of embodiment 1 is optimal.
Although above the present invention is made to retouch in detail with general explanation, embodiment and experiment
State, but on the basis of the present invention, it can be made some modifications or improvements, this is apparent to those skilled in the art
's.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to claimed
Scope.
Claims (10)
- A kind of 1. Maca composite, it is characterised in that by weight, including following component：0.25~2 part of maca water extract, Huang Smart 0.25~2.5 part of water extract, 0.25~2.5 part of campanulaceae water extract.
- 2. Maca composite according to claim 1, it is characterised in that parts by weights meter, including following component：Maca water carries 0.25~1 part of thing, 0.25~1 part of sealwort water extract, 0.25~1 part of campanulaceae water extract；Preferably, the mass ratio of the sealwort water extract and the campanulaceae water extract is 1:1.
- 3. Maca composite according to claim 1 or 2, it is characterised in that the maca water extract, and/or sealwort water carry Thing, and/or the following preparation method of use of campanulaceae water extract：It is in mass ratio 1 after maca or sealwort or campanulaceae are crushed:15 ~25 ratio is added to the water, and ultrasonic extraction 1~3 time, takes clear liquid；After carrying out deproteinized processing again, water extract solution is made, does Dry powder processed, to obtain the final product.
- 4. Maca composite according to claim 3, it is characterised in that the ultrasonic extraction is specially：It is placed on 55 DEG C At a temperature of~65 DEG C, with 25~35min of power ultrasonic of 220~280W, centrifugation, takes clear liquid.
- 5. the Maca composite according to claim 3 or 4, it is characterised in that the albumen processing includes the following steps：1) concentrate by clear liquid concentration for 1/3~1/4 volume；2) it is 3~4 by volume:1 ratio, in the concentrate that step 1) obtains, adds organic solvent, after being sufficiently mixed, Obtain organic phase and water phase；3) water for being obtained step 2) mutually repeats the organic solvent of 2~3 additions, 3~4 times of volumes, after being sufficiently mixed, must have Machine phase and water phase；4) combining step 2) and the organic phase that is obtained of step 3), supernatant is taken after centrifugation, then the water phase obtained with step 3) Merge, up to water extraction solution.
- 6. Maca composite according to claim 5, it is characterised in that the organic solvent is the mixing of chloroform and n-butanol Thing；Preferably volume ratio is 3:1 chloroform and the mixture of n-butanol.
- 7. according to any Maca composite of claim 1~6, it is characterised in that the maca water extract, and/or sealwort Water extract, and/or the preparation method of campanulaceae water extract include the following steps：1) after crushing maca or sealwort or campanulaceae, 50~70 mesh sieves is crossed, are in mass ratio 1:18~22 ratio is added to the water, At a temperature of being placed on 58 DEG C~62 DEG C, with 28~32min of power ultrasonic of 240~260W, centrifugation, takes clear liquid；By described in Clear liquid concentration is the concentrate of 1/3~1/4 volume；2) it is 3~4 by volume:1 ratio, in the concentrate that step 1) obtains, adds the mixed liquor of chloroform and n-butanol, After being sufficiently mixed, organic phase and water phase are obtained；3) water for being obtained step 2) mutually repeats the chloroform of 2~3 additions, 3~4 times of volumes and the mixed liquor of n-butanol, fully After mixing, organic phase and water phase are obtained；4) combining step 2) and the organic phase that is obtained of step 3), supernatant is taken after centrifugation, then the water phase obtained with step 3) Merge, up to water extraction solution, dry powder processed, to obtain the final product；Wherein, the volume ratio of chloroform and n-butanol is 3:1.
- 8. Maca composite according to claim 1, it is characterised in that by weight, including following component：Maca water carries 0.8~1.2 part of thing, 0.4~0.6 part of sealwort water extract, 0.4~0.6 part of campanulaceae water extract；The sealwort water extract and the tangerine The mass ratio for obstructing water extract is 1:1；Preferably：The Maca composite, by weight, including following component：1 part of maca water extract, sealwort water extract 0.5 Part, 0.5 part of campanulaceae water extract.
- 9. application of any Maca composite of claim 1~8 on glucose -lipid metabolism disorder medicine or health products are improved.
- 10. application according to claim 9, it is characterised in that the medicine or health products are in insulin resistance, glycosuria Disease, hyperglycaemia, hyperlipidemia, obesity, the application in fatty liver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711329213.9A CN107970367A (en) | 2017-12-13 | 2017-12-13 | A kind of Maca composite for improving glucose -lipid metabolism disorder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711329213.9A CN107970367A (en) | 2017-12-13 | 2017-12-13 | A kind of Maca composite for improving glucose -lipid metabolism disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107970367A true CN107970367A (en) | 2018-05-01 |
Family
ID=62010154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711329213.9A Pending CN107970367A (en) | 2017-12-13 | 2017-12-13 | A kind of Maca composite for improving glucose -lipid metabolism disorder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107970367A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104187681A (en) * | 2014-09-18 | 2014-12-10 | 云南省农业科学院高山经济植物研究所 | Hypoglycemic and hypolipidemic health food and preparation method thereof |
-
2017
- 2017-12-13 CN CN201711329213.9A patent/CN107970367A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104187681A (en) * | 2014-09-18 | 2014-12-10 | 云南省农业科学院高山经济植物研究所 | Hypoglycemic and hypolipidemic health food and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| ROSTISLAV VECERA等: "The Influence of Maca (Lepidium meyenii) on Antioxidant Status, Lipid and Glucose Metabolism in Rat", 《PLANT FOODS FOR HUMAN NUTRITION》 * |
| 闫鸿丽等: "黄精调节糖代谢的活性及作用机理研究进展", 《中国现代中药》 * |
| 陈桂芳: "桔梗抗糖尿病药理研究进展", 《绵阳师范学院学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106616979B (en) | Preparation method and application of turmeric fruit and vegetable enzyme | |
| CN107594270B (en) | Polypeptide herbal solid beverage with antioxidant function | |
| CN103284039A (en) | Weight-reducing composition and preparation method thereof | |
| CN106579387A (en) | Arabinose-enzyme composition and preparation method thereof | |
| CN100456938C (en) | Hypolipidemic milk powder and its prepn process | |
| CN105211880A (en) | A kind of preparation method of fig ferment | |
| CN102511861A (en) | Thickened red jujube pulp added with oligosaccharide | |
| CN102511864B (en) | Jujube high-consistency stock | |
| CN110214935A (en) | A kind of formula and production method of pectase collagen fibre drink | |
| CN106578077A (en) | Milk tea containing kelp dietary fibers and preparation method thereof | |
| CN102613453B (en) | Marine organism type enteral nutrition preparation for diabetes patients, preparation method of marine organism type enteral nutrition preparation and application | |
| CN106072133B (en) | A kind of preparation method with anti-oxidant and lipid-metabolism adjustment effect compound berry fine powder | |
| CN110236055A (en) | A kind of pectase beverage of protect liver and preparation method thereof | |
| CN106889389A (en) | A kind of wild white bur oral liquid and preparation method thereof | |
| CN103704348A (en) | Donkey milk powder formula for boosting brain, nourishing blood and improving resistance based on homology of medicine and food | |
| CN106954656A (en) | A kind of mulberry leaf tea powder biscuit and preparation method thereof | |
| CN107970367A (en) | A kind of Maca composite for improving glucose -lipid metabolism disorder | |
| CN110279050A (en) | A kind of pectase beverage of detoxicating intestine and preparation method thereof | |
| CN107095300A (en) | A kind of biological nutrition compound composition of auxiliary treatment diabetes | |
| CN108450941A (en) | A kind of dietary composition adjusting lipid metaboli | |
| CN108936183A (en) | A kind of compound endothelium corneum gigeriae galli solid beverage | |
| CN114246281A (en) | Oyster peptide and sea cucumber peptide sports flavor beverage and preparation method thereof | |
| CN107177638A (en) | The highly enriched fermentation process and its active product of Yunnan olive polyphenol | |
| CN110089653B (en) | Formula of hypolipidemic polypeptide herbal solid beverage and preparation method of bone marrow peptide powder | |
| KR101391647B1 (en) | Anti obesity composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180501 |
|
| RJ01 | Rejection of invention patent application after publication |